横浜市立大学大学院 医学研究科 幹細胞免疫制御内科学 血液・膠原病内科学

About教室概要

業績

2025年

血液グループ

原著論文: 症例報告を含む

  1. Akimoto M, Miyazaki T, Takahashi H, Takeda T, Hibino Y, Tokunaga M, Ohashi T, Matsumura A, Teshigawara H, Suzuki T, Teranaka H, Nakajima Y, Matsumoto K, Hashimoto C, Fujimaki K, Fujita H, Sakai R, Fujisawa S, Nakajima H：Delayed Methotrexate Elimination Following High-dose Methotrexate Prophylaxis in High-risk Diffuse Large B-cell Lymphoma．Intern Med，64(18)：2716-2722，2025．
  2. Akahoshi Y, Inamoto Y, Spyrou N, Nakasone H, Diniz MA, Asada N, Ayuk F, Choe HK, Doki N, Eto T, Etra AM, Hexner EO, Hiramoto N, Hogan WJ, Holler E, Kataoka K, Kawakita T, Tanaka M, Tanaka T, Uchida N, Vasova I, Yoshihara S, Ishimaru F, Fukuda T, Chen YB, Kanda J, Nakamura R, Atsuta Y, Ferrara JLM, Kanda Y, Levine JE, Teshima T：Refinement of day 28 treatment response criteria for acute GVHD: a collaboration study of the JSTCT and MAGIC．Blood Adv，9(18)：4640-4653，2025．
  3. Akahoshi Y, Nakasone H, Takenaka K, Ara T, Tada Y, Doki N, Uchida N, Tanaka M, Hasegawa Y, Takeda W, Nishida T, Ishikawa J, Kurita N, Sawa M, Onizuka M, Kako S, Fujiwara SI, Kataoka K, Kawamura K, Fukuda T, Atsuta Y, Yakushijin K, Kanda Y：Heterogeneity of Survival Benefit Conferred By Letermovir．Transplant Cell Ther，31(7)：461.e1-461.e12，2025．
  4. Fujii T, Sakurai M, Shimizu H, Izumi A, Kimura K, Shono K, Tanoue S, Okada Y, Kako S, Matsui S, Sakaida E, Jinguji A, Ouchi F, Najima Y, Kobayashi T, Tachibana T, Tanaka M, Iwata S, Onizuka M, Yano S, Hatano K, Hagihara M, Aotsuka N, Fujisawa S, Takahashi S, Kobayashi N, Kikuchi T, Tanaka K, Kataoka K, Kanda Y：Impact of prior solid tumors and their treatment modality on outcomes after allogeneic hematopoietic stem cell transplantation．Bone Marrow Transplant，60(12)：1601-1610，2025．
  5. Fujimoto A, Miyazaki K, Yakushijin K, Fujino T, Munakata W, Ejima Y, Maruyama D, Kubota N, Maeda T, Takizawa J, Hiramoto N, Takeuchi M, Sakai R, Fukuhara N, Taguchi S, Asano N, Yamaguchi M, Suzuki R：Improved prognosis of advanced-stage extranodal NK/T-cell lymphoma: results of the NKEA-Next study．Leukemia，39(4)：909-916，2025．
  6. Harada K, Kanda J, Hirayama M, Wada F, Uchida N, Tanaka M, Nakamae H, Tokunaga M, Ishiwata K, Onizuka M, Hasegawa Y, Fukuda T, Eto T, Kurita N, Kawakita T, Jinguji A, Ishimaru F, Atsuta Y, Nakasone H：Comparison of Nonrelapse Mortality After Haploidentical Hematopoietic Stem Cell Transplantation With Post-transplant Cyclophosphamide Versus Single Umbilical Cord Blood Transplantation in Hematologic Disease．Transplant Cell Ther，31(2)：103.e1-103.e13，2025．
  7. Hayakawa F, Mori N, Imai K, Yokoyama Y, Katsuoka Y, Saito T, Murayama T, Yamazaki E, Sato S, Atsuta Y, Ishikawa Y, Sakaida E, Hatta Y, Matsumura I, Miyazaki Y, Kiyoi H；Japan Adult Leukemia Study Group (JALSG)：Nelarabine-combined chemotherapy improves outcome of T-cell acute lymphoblastic leukemia but shows more severe neurotoxicity: JALSG T-ALL213-O．Cancer Sci，116(2)：453-461，2025．
  8. Hibino Y, Fujisawa S, Fujimaki K, Hagihara M, Fujita H, Tanaka M, Takayama K, Takeda T, Matsumura A, Suzuki T, Ishii Y, Nakajima Y, Miyazaki T, Nakajima H：Clinical applicability of the ELN2020 criteria for tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia: insights from a multicenter retrospective study in real-world practice．Leuk Res，152：107689，2025．
  9. Ichikawa K, Adachi S, Takase-Minegishi K, Nakayama Y, Nagasawa Y, Iizuka Y, Maeda A, Hirahara L, Soejima Y, Ohashi T, Kunimoto H, Horita N, Yoshimi R, Kirino Y, Nakajima H：Distinct features of trisomy 8-associated autoinflammatory disease from Behcet’s disease: Case series and systematic review．Clin Exp Rheumatol，43(10)：1718-1725，2025．
  10. Ikeda J, Kunimoto H, Saito Y, Tsujimoto S, Takeuchi M, Miura A, Kurosawa T, Murakami K, Kato I, Funakoshi-Tago M, Yokoyama A, Shiba N, Adachi S, Tomizawa D, Tamura T, Ito S, Nakajima H：Metabolic reprogramming by PRDM16 drives cytarabine resistance in acute myeloid leukemia．Haematologica，110(11)：2647-2660，2025．
  11. Ikeda J, Shiba N, Kato S, Kunimoto H, Saito Y, Sagisaka M, Ito M, Goto H, Okuno Y, Nakamura W, Yoshitomi M, Takeuchi M, Ito S, Nakajima H, Kato M, Tsujimoto S：Establishment of a high-risk pediatric AML-derived cell line YCU-AML2 with genetic and metabolic vulnerabilities．Int J Hematol，121(5)：694-705，2025．
  12. Ishii Y, Fujisawa S, Miyazaki T, Nakajima Y, Matsumura A, Fujimaki K, Suzuki T, Hagihara M, Tanaka M, Hashimoto C, Nakajima H：Real-world toxicity and efficacy of asciminib in heavily pretreated patients with chronic myeloid leukemia．Int J Hematol，121(2)：187-193，2025．
  13. Itonaga H, Miyazaki Y, Fujioka M, Kurosawa S, Nagata Y, Shimazu Y, Ueda T, Uchida N, Doki N, Nishida T, Asada N, Tanaka M, Takada S, Sakurai M, Kurokawa M, Yoshimitsu M, Kanda Y, Ichinohe T, Atsuta Y, Tachibana T；adult MDS and CML/MPN working groups of the Japanese Society for Transplantation and Cellular Therapy：Differential impact of graft-versus-host disease on post-transplant outcomes of chronic myelomonocytic leukemia according to transplant procedures．Leuk Res，159：108134，2025．
  14. Iriyama N, Takahashi N, Fujimaki K, Ono T, Saburi M, Yamamoto M, Kimura F, Kondo E, Aotsuka N, Yokoyama H, Katagiri S, Minami Y, Ishikawa M, Kuwatsuka Y, Miura M, Saito A, Saito T, Matsumura I, Miyazaki Y, Sakaida E, Maeda Y, Yamauchi T, Kiyoi H：Reattempt of tyrosine kinase inhibitor discontinuation after maintenance therapy with ponatinib in patients with chronic myeloid leukemia in the chronic phase: result of JALSG CML RE-STOP219 study．Blood，146(Suppl 1)：○○○-○○○，2025．
  15. Izumi A, Tachibana T, Ishii H, Fujiwara SI, Najima Y, Ohwada C, Yoshifuji K, Hibino Y, Tanaka M, Kako S, Kimura SI, Tamaki M, Yano S, Yokoyama H, Minakata D, Tsukamoto S, Sakaida E, Doki N, Yokota A, Miyazaki T, Aotsuka N, Kanda Y：Prognostic value of C-reactive protein/platelet ratio as a biomarker prior to allogeneic hematopoietic stem cell transplantation in malignant lymphoma．Hematol Oncol，43(5)：e70136，2025．DOI: 10.1002/hon.70136．
  16. Izumi A, Tachibana T, Nukui J, Miyazaki T, Hirose N, Ohashi T, Tanaka M, Katsuki K, Suzuki T, Nakajima Y, Matsumoto K, Fujisawa S, Tanaka M, Nakajima H：Clinical significance of C-reactive protein/platelet ratio from diagnosis to allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia．Ann Hematol，104(7)：3733-3743，2025．DOI: 10.1007/s00277-025-06470-3．
  17. Izutsu K, Ishikawa T, Shimada K, Kubo K, Kondo T, Fujimoto K, Fujisaki T, Kurahashi S, Nagafuji K, Sakai R, Jo T, Nakazato T, Sunami K, Kasahara S, Cohen A, Takai M, Zhong J, Takeuchi M：Zanubrutinib in Japanese treatment-naive and relapsed/refractory patients with Waldenström macroglobulinemia and CLL/SLL．Int J Hematol，121(4)：483-493，2025．
  18. Jabbour E, Lussana F, Sanchez PM, Torrent A, Rifón J, Agrawal V, Tormo M, Cassaday RD, Cluzeau T, Huguet F, Papayannidis C, Rivas JMH, Rijneveld A, Fleming S, Vucinic V, Böll B, Ikezoe T, Abdul-Hay M, Savoie ML, Schuh A, Schwartz S, Chiaretti S, Yuda J, Miyazaki T, González-Campos J, Brüggemann M, Zhang J, Choudhry J, Guest E, Kantarjian H：Efficacy of single-agent subcutaneous blinatumomab in adults with relapsed/refractory B-cell acute lymphoblastic leukemia: results from a phase 1/2 dose expansion study with extended follow-up．Blood，146(Suppl 1)：○○○-○○○，2025．
  19. Jabbour E, Rambaldi A, Martínez-Sánchez P, Catarineu AT, Rifón JJ, Agrawal V, Diaz MT, Cassaday RD, Cluzeau T, Huguet F, Papayannidis C, Hernández-Rivas JM, Rijneveld A, Fleming S, Vucinic V, Böll B, Ikezoe T, Abdul-Hay M, Savoie ML, Schuh AC, Berthon C, Schwartz S, Chiaretti S, Yuda J, Miyazaki T, González-Campos J, Chen Y, Zugmaier G, Guest E, Gordon P, Kantarjian H：Safety and efficacy of single-agent subcutaneous blinatumomab in adults with relapsed/refractory B-cell acute lymphoblastic leukemia: results from a phase 1/2 dose expansion study．HemaSphere，9(S1)：○○○-○○○，2025．
  20. Kato H, Ohya T, Koizumi T, Iida M, Takano S, Hata M, Nakajima H, Mitsudo K.Infectious Complications in Patients Receiving Superselective Intra-Arterial Chemoradiotherapy for Oral Squamous Cell Carcinoma.Oral Dis. 2025，7. doi: 10.1111/odi.70027.
  21. Kimura SI, Kawamura S, Toya T, Okinaka K, Hosoi H, Uchida N, Doki N, Nishida T, Tanaka M, Hasegawa Y, Kanda Y, Asada N, Kurita N, Nakamae H, Eto T, Yoshimitsu M, Onizuka M, Fukuda T, Ohbiki M, Atsuta Y, Yakushijin K：Letermovir prophylaxis and risk of bacterial or fungal infection after allogeneic hematopoietic cell transplantation．J Infect Chemother，32(1)：102888，2026．
  22. vKondo K, Shimizu H, Kako S, Tachibana T, Izumi A, Sakaida E, Shono K, Fukuda T, Najima Y, Shindo T, Sakurai M, Kimura S, Tanaka M, Tsukamoto S, Naganuma K, Tabayashi T, Machida S, Onizuka M, Takada S, Fujisawa S, Kataoka K, Doki N, Kanda Y：Nelarabine treatment before allogeneic stem cell transplantation was associated with an increased risk of neurological adverse events in patients with T-ALL/LBL: a retrospective study of the Kanto Study Group for Cell Therapy．Blood，146(Suppl 1)：2025．
  23. Kuji S, Nozawa K, Toma S, Arao H, Imoto S, Kajiyama H, Kitano A, Kodera Y, Saito R, Sakai R, Taketomi A, Nakayama R, Hiyama E, Futamura M, Matsui M, Yonemura M, Oya M, Suzuki N：Survey of healthcare professionals’ awareness of appearance care for Japanese cancer patients and their institutions’ appearance care systems: report from the Japan Society of Clinical Oncology．Int J Clin Oncol，30(4)：655-665，2025．
  24. Kunimoto H, Miura A, Sagisaka M, Ito M, Maenosono R, Yamauchi H, Nishimura K, Honma D, Tsutsumi S, Adachi A, Sakuma T, Ohashi T, Teranaka H, Ikeda J, Samukawa S, Toya T, Harada Y, Doki N, Cai SF, Maki H, Goto H, Yoshimi A, Nakajima H：PRC2-mediated apoptosis evasion is a therapeutic target of MDS/AML with inv(3)/t(3;3) and monosomy 7．Int J Hematol，122(Suppl 1)：2025．
  25. Matsubara Y, Masuishi T, Hosoda W, Hirano H, Mishima S, Takahashi H, Otsuka T, Kawasaki K, Kawakami T, Yanagihara K, Shimura T, Komoda M, Murayama K, Minashi K, Yamamoto Y, Shinohara Y, Nishina S, Musha N, Kato K, Kawakami K, Shinozaki K, Tsuchihashi K, Ando T, Kito Y, Makiyama A, Mitani S, Hino K, Izawa N, Oze I, Muro K：Ramucirumab-containing chemotherapy for patients with gastrointestinal neuroendocrine carcinoma refractory/intolerant to platinum-based chemotherapy: A multicenter observational retrospective study (WJOG13420G)．Int J Cancer，157(12)：2577-2588，2025．
  26. Konishi H, Tachibana T, Arai S, Izumi A, Takeda T, Hirose N, Nukui J, Sato S, Suzuki T, Ishii R, Yamazaki E, Matsunawa M, Mukae J, Takahata A, Tanaka M, Suzuki T, Nakajima H：Comparison of clinical outcomes between preemptive and maintenance therapy after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia．Int J Hematol，122(4)：546-558，2025．
  27. Maruyama D, Fukuhara N, Ishizawa K, Sano Y, Machida R, Makita S, Munakata W, Ota S, Ichikawa M, Negoro E, Murayama T, Suzuki R, Yoshida I, Morimoto H, Tokunaga M, Ohmachi K, Takahashi H, Suehiro Y, Yoshida S, Nosaka K, Kawakita T, Sekiguchi Y, Kataoka K, Murakami S, Maruta M, Takase K, Makiyama J, Ishitsuka K, Tsukasaki K, Nagai H：Impact of rituximab early administration on outcomes in advanced-stage low-tumor-burden follicular lymphoma: subgroup analysis of phase III JCOG1411/FLORA study．Hematol Oncol，43(S2)：2025．
  28. Munakata W, Takahashi H, Rai S, Shirouchi Y, Kitazume K, Saito T, Kanemura N, Hattori K, Tatetsu H, Okamoto A, Yokohama A, Ohta M, Murakami S, Imai T, Sakai H, Maseki N, Kuroda J, Saito A, Yoshimura T, Yamamoto K, Kagoo T, Suzuki T, Shimada K, Fukuhara S, Taketsuna M, Suzuki R, Tsukasaki K, Izutsu K：The FOREST study: a prospective observational study on real-world management and outcomes of lymphoma in Japan．Hematol Oncol，43(S2)：2025．
  29. Nakajima H, Kunimoto H：VEXAS syndrome．Int J Hematol，122(3)：341-350，2025．
  30. Nato Y, Miyazaki K, Maruyama D, Takahashi H, Sunami K, Murakami S, Negoro E, Miyazawa Y, Choi I, Okada T, Takayama N, Tomita N, Momose S, Kaneda Y, Yoshida M, Gomyo H, Toyama K, Nishikori M, Saito A, Hiraga J, Masunari T, Takahashi N, Makiyama J, Suzuki T, Tsunemine H, Takizawa J, Kato T, Masaki Y, Fukuhara N, Okamoto M, Tawara I, Asano N, Ohshima K, Izutsu K, Kato K, Suzuki R, Yamaguchi M：Treatments and Outcomes of Newly Diagnosed CD5-Positive Diffuse Large B-Cell Lymphoma: A Multi-Institutional Observational Study．Hematol Oncol，43(2)：e70047，2025．
  31. Oda Y, Sato K, Kunisada K, Yogo M, Takei T, Ogura M, Kikuchi T, Abe Y, Tsukada N, Ishida T：Successful management of cardiac arrest due to cytokine release syndrome following chimeric antigen receptor T-cell therapy for multiple myeloma．Rinsho Ketsueki，66(8)：749-755，2025．
  32. Ohashi T, Kunimoto H, Adachi A, Miura A, Sakuma T, Ikeda J, Ino Y, Soeda H, Harada J, Shimosato Y, Yamamoto K, Kimura Y, Goyama S, Fujii S, Tamura T, Honda H, Nakajima H：CblQ367P cooperates with loss of Tet2 to drive a CNL-like disease via the NF-kB pathway．Int J Hematol，122(Suppl 1)：2025．
  33. Okada Y, Tachi N, Shimazu Y, Murata M, Nishiwaki S, Onishi Y, Jinguji A, Uchida N, Tanaka M, Hasegawa Y, Ito A, Kako S, Nishida T, Onodera K, Sawa M, Nakamae H, Toyosaki M, Kanda Y, Onizuka M, Fukuda T, Ohbiki M, Atsuta Y, Arai Y, Tachibana T：Comparing de novo chronic myeloid leukemia in blastic phase with Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation．Cancer，131(1)：e35627，2025．
  34. Ono T, Okada T, Takahashi T, Minami Y, Nakaseko C, Iriyama N, Fujimaki K, Kakihana K, Ogasawara Y, Okada M, Tauchi T, Atsuta Y, Ohtake S, Miyamoto T, Ohnishi K, Sakaida E, Fujisawa S, Kobayashi Y, Asou N, Naoe T, Kiyoi H, Miyazaki Y, Matsumura I：Early prediction of MR4.5 attainment and sustained response in chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors: analysis from the JALSG CML212 Road to MR4.5 Study．HemaSphere，9(S1)：2025．
  35. Saburi M, Masunari T, Fukuhara N, Inagaki Y, Shimura A, Imoto N, Hasegawa Y, Hagihara M, Kobayashi N, Kumekawa H, Nakazawa H, Miyazaki K, Kawakita T, Isshiki T, Katsube A, Fujisawa S, Horigome Y, Koba Y, Jinnouchi F, Sekiguchi N：The impact of tirabrutinib monotherapy for the treatment of Bing-Neel syndrome: a multicenter retrospective study．Am J Hematol，100(10)：1912-1915，2025．DOI: 10.1002/ajh.70029．
  36. Sadaga Y, Najima Y, Tachibana T, Harada K, Misaki Y, Morita K, Yokoyama H, Sakaida E, Fujiwara S, Takada S, Shimizu H, Aotsuka N, Izumi A, Miyazaki T, Yokota A, Kako S, Toubai T, Tanaka M, Takahashi S, Yano S, Doki N, Kanda Y：Serum albumin, but not GNRI, is an independent prognostic factor for survival after first allogeneic SCT: a large-scale multicenter analysis．Blood，146(Suppl 1)：2025．
  37. Sakuma T, Kunimoto H, Kitane A, Adachi A, Miura A, Shirafuta M, Ohashi T, Ikeda J, Kato I, Enaka M, Suzuki M, Fujii S, Tamura T, Yamamoto M, Nakajima H：Cooperative activation of NF-κB by inv(3)/t(3;3) and NRAS mutations drives myeloid leukemogenesis．Blood，146(Suppl 1)：2025．
  38. Sasaki H, Suzuki T, Maruyama D, Munakata W, Kusumoto S, Yoshimura K, Takayama N, Ozaki S, Mima F, Murayama K, Izutsu K, Takahashi N, Takahashi H, Suzuki Y, Mishina T, Yagi Y, Maruta M, Tatetsu H, Tomita N, Kawaguchi Y, Sakurai M, Furukawa K, Nakamura M, Makiyama J, Harada Y, Iriyama C, Tada Y, Fujino T, Sasaki N, Asao Y, Isayama M, Saburi M, Masaki Y, Hatta S, Nakamura N, Arakawa Y, Hattori K, Kato T, Inagaki A, Nagata Y, Ida N, Kanamori T, Kobayashi T, Iida S：Treatment patterns and outcomes for large B-cell lymphoma patients with central nervous system relapse: a multicenter retrospective study (CoNSensus Study)．Blood，146(Suppl 1)：2025．
  39. Sekiguchi N, Masunari T, Fukuhara N, Inagaki Y, Shimura A, Imoto N, Hasegawa Y, Hagihara M, Kobayashi N, Kumekawa H, Nakazawa H, Miyazaki K, Kawakita T, Isshiki T, Katsube A, Fujisawa S, Suzuki T, Maruyama D, Kato K, Saburi M：The impact of tirabrutinib, a second-generation Bruton’s tyrosine kinase inhibitor, for Bing-Neel syndrome: a multicenter retrospective study．HemaSphere，9(S1)：○○○-○○○，2025．
  40. Suzuki T, Machida R, Sano Y, Shimada K, Iida S, Yamauchi N, Nakamura N, Handa H, Hori Y, Suzuki Y, Ogiya D, Kataoka K, Negoro E, Takahashi H, Kuroda J, Makiyama J, Hanamura I, Miyashita K, Ito S, Uryu H, Kusumoto S, Takeuchi M, Harada Y, Kumode T, Suzuki R, Yoshida I, Harada N, Munakata W, Nagai H, Maruyama D：Role of bortezomib maintenance therapy in the anti-CD38 antibody era: interim analysis result of a randomized phase III study for transplant-ineligible newly diagnosed multiple myeloma (JCOG1911/B-DASH Study)．Blood，146(Suppl 1)：2025．
  41. Tachibana T, Izumi A, Katsuki K, Konishi H, Arai S, Takeda T, Akimoto M, Saito M, Tanaka M, Nakajima H：Investigation of pre-transplant biomarkers predicting SOS/VOD．Int J Hematol，122(Suppl 1)：2025．
  42. Tachibana T, Izumi A, Arai S, Takeda T, Hirose N, Tamai Y, Sato S, Hashimoto C, Fujimaki K, Ishii R, Sakai H, Yamazaki E, Inoue Y, Tanaka M, Nakajima H：Preconditioning intervention prior to allogeneic hematopoietic stem cell transplantation in patients with high-risk acute myeloid leukemia．Exp Hematol，144：104746，2025．
  43. Takagi F, Ono T, Takahashi N, Minami Y, Nakaseko C, Iriyama N, Fujimaki K, Kakihana K, Ogasawara Y, Okada M, Tauchi T, Atsuta Y, Suzuki R, Yamamoto K, Ohtake S, Miyamoto T, Ohnishi K, Sakaida E, Fujisawa S, Kobayashi Y, Kawaguchi T, Kizaki M, Asou N, Naoe T, Kiyoi H, Miyazaki Y, Matsumura I：The EUTOS Long-Term Survival Score Predicts Failure-Free Survival in Chronic Myeloid Leukemia Patients in the Era of Second-Generation Tyrosine Kinase Inhibitors: analysis from JALSG-JSH CML Study．HemaSphere，9(S1)：2025．
  44. Takahashi H, Sakai R, Hirose N, Hibino Y, Tokunaga M, Nakajima H：Poor outcome of older patients with diffuse large B-cell lymphoma after progression．J Clin Exp Hematop，65(1)：40-48，2025．
  45. Takahashi N, Kimura S, Matsuki E, Ono T, Doki N, Iino M, Sawa M, Saburi Y, Murai K, Fujimaki K, Kurahashi S, Iriyama N, Onaka T, Sakaida S, Yoshida C, Sato K, Miyamoto T, Takaku T, Shiratsuchi M, Kimura F, Katagiri S, Yamamoto M, Saito A, Matsumura I：Five-year interim analysis of multi-institutional collaborative study for estimating the persistence of treatment-free remission in chronic myeloid leukemia after stopping tyrosine kinase inhibitor in Japan: J-SKI．Blood，146(Suppl 1)：2025．
  46. Takayama K, Nakajima Y, Miyazaki T, Matsumoto K, Yamanokawa H, Yamada Y, Shinmura K, Hibino Y, Shirafuta M, Nukui J, Tanaka M, Teshigawara H, Ishii Y, Hagihara M, Fujisawa S, Nakajima H：Factors predicting spontaneous regression in other iatrogenic immunodeficiency-associated lymphoproliferative diseases．Clin Lymphoma Myeloma Leuk，25(7)：e466-e473，2025．DOI: 10.1016/j.clml.2025.02.008．
  47. Tanaka N, Shinohara A, Kimura SI, Kobayashi S, Uchida N, Asada N, Ota S, Tanaka M, Arai Y, Kataoka K, Hagihara M, Onizuka M, Nakamura Y, Matsuoka KI, Kawamura K, Kanda J, Fukuda T, Atsuta Y, Nakasone H：The limited impact of pre-existing rheumatologic diseases on outcomes of allogeneic hematopoietic stem cell transplantation: a nationwide propensity-score matched analysis．Transplant Cell Ther，2025．
  48. Toya T, Nakajima Y, Hara K, Kaito S, Nishida T, Uchida N, Shingai N, Takeda W, Ozawa Y, Tanaka M, Yoshihara S, Katayama Y, Eto T, Sawa M, Ota S, Ohigashi H, Takada S, Kataoka K, Kanda J, Fukuda T, Ogata M, Taguchi A, Atsuta Y：Machine learning algorithm to explore patients with heterogeneous treatment effects of clinically significant CMV infection and non-relapse mortality after HSCT．EJHaem，6(4)：e70117，2025．
  49. Washimi K, Kasajima R, Sato S, Nezu Y, Takahashi H, Sakai R, Nakamura N, Takagi M, Hasegawa C, Yoshioka E, Okubo Y, Katayama K, Imoto S, Yokose T, Miyagi Y：Chemokine expression in well-differentiated liposarcoma may be involved in the tumorigenesis of lymphoplasmacytic lymphoma: a case study．Cancer Rep，8(2)：e70129，2025．
  50. Watanabe N, Takaku T, Iriyama N, Iwanaga E, Kimura Y, Ishikawa M, Nakayama H, Sato E, Tabayashi T, Mitsumori T, Nakazato T, Tokuhira M, Fujita H, Ando M, Miura K, Kawaguchi T：The incidence of vascular adverse events and usefulness of novel risk assessment tool in Japanese patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors．Cardiooncology，11(1)：68，2025．
  51. Yanada M, Yamasaki S, Mizuno S, Sugita J, Fujino T, Misaki Y, Tanaka M, Uchida N, Onizuka M, Doki N, Ota S, Sawa M, Kawakita T, Hasegawa Y, Nakamae H, Ishiwata K, Hiramoto N, Ishimaru F, Kanda J, Ohbiki M, Atsuta Y, Nakasone H, Konuma T：Comparison of single-unit umbilical cord blood transplantation and haploidentical transplantation using posttransplant cyclophosphamide during first complete remission of acute myeloid leukemia．Bone Marrow Transplant，61(1)：18-25，2026．
  52. Yokoyama H, Fuji S, Murata M, Hirayama M, Wake A, Uchida N, Tanaka M, Onizuka M, Takahashi S, Doki N, Maruyama Y, Ishiwata K, Uehara Y, Nishida T, Sawa M, Kawakita T, Eto T, Ishimaru F, Kato K, Ichinohe T, Atsuta Y, Terakura S, Morishima S：Impact of graft-versus-host disease on outcomes of cord blood transplantation according to HLA disparity and its prophylaxis type．Ann Hematol，104(5)：2905-2913，2025．
  53. Yoshimitsu M, Tanaka T, Nakano N, Kato K, Muranushi H, Tokunaga M, Ito A, Ishikawa J, Eto T, Morishima S, Kawakita T, Itonaga H, Uchida N, Tanaka M, Akizuki K, Ishitsuka K, Ohigashi H, Ota S, Ando T, Kanda Y, Fukuda T, Atsuta Y, Fuji S；ATL Working Group of the Japanese Society for Transplantation and Cellular Therapy：Comparative outcomes of various transplantation platforms, highlighting haploidentical transplants with post-transplantation cyclophosphamide for adult T-cell leukaemia/lymphoma．Br J Haematol，206(1)：235-249，2025．
  54. Zang W, Koike Y, Nishimura K, Tanaka A, Yamazaki H, Yamasaki T, Ito H, Zhang Y, Aoyama Y, Saika W, Xiao M, Hasegawa C, Kunimoto H, Nakajima H, Ishikawa F, Takaori-Kondo A, Inoue D：BRD4 and MYB inhibition overcomes venetoclax resistance in EVI1-rearranged acute myeloid leukemia．Sci Rep，15(1)：37099，2025，10　 doi: 10.1038/s41598-025-21034-1.

ページトップへ